Eyenovia
ISIN: US30234E1047 | Symbol: EYEN
Market Cap 54.51M
Shs Float 9.74M
Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of hyperemia, pruritis, and dry eye; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Sehr viele Insiderkäufe:
http://openinsider.com/search?q=eyen
Presentation:
http://ir.eyenoviabio.com/static-files/...6161-4048-95fa-9202d360aae8
3x Phase 3 Medikamente kürz vor der Fertigstellung bzw. Zulassungsentscheidung FDA
|
